Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.004 AUD | -20.00% | 0.00% | -55.56% |
03:43am | OncoSil Medical Raises AU$5.3 Million under Entitlement Offer | MT |
04-18 | OncoSil Medical Treats Two More Patients in Netherlands in Pancreatic Cancer Trial | MT |
Business Summary
Sales per Business
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Device Development for New Medical Treatment
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +58.63% |
Sales per region
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Australia and New Zealand
69.6
%
| 0 | 100.0 % | 0 | 69.6 % | +10.40% |
Europe
30.4
%
| - | - | 0 | 30.4 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Nigel Lange
CEO | Chief Executive Officer | - | 03/05/20 |
Christian Cin
DFI | Director of Finance/CFO | - | 31/05/23 |
Jon Bell
CTO | Chief Tech/Sci/R&D Officer | - | - |
Henk Tissing
CTO | Chief Tech/Sci/R&D Officer | - | - |
David Turner
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/20 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Nigel Lange
CEO | Chief Executive Officer | - | 03/05/20 |
Douglas Cubbin
CHM | Chairman | - | 06/08/23 |
Director/Board Member | - | 13/07/23 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 3,103,954,978 | 1,715,689,736 ( 55.27 %) | 0 | 55.27 % |
Company contact information
Sector
Sales per region
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-55.56% | 7.33M | |
+29.68% | 699B | |
+25.07% | 571B | |
-4.35% | 364B | |
+17.65% | 326B | |
+3.77% | 286B | |
+14.68% | 236B | |
+4.71% | 198B | |
-12.43% | 194B | |
-3.79% | 154B |
- Stock Market
- Equities
- OSL Stock
- Company OncoSil Medical Limited